Cardax, Inc. – OTC:CDXI

Cardax stock price today

$0
+0.00
+100%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cardax stock price monthly change

-100.00%
month

Cardax stock price quarterly change

-100.00%
quarter

Cardax stock price yearly change

-100.00%
year

Cardax key metrics

Market Cap
 161
Enterprise value
 5.33M
P/E
 N/A
EV/Sales
 10.65
EV/EBITDA
 -1.76
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 -1085.42%
Oper. margin
 -584.76%
Gross margin
 65.75%
EBIT margin
 -584.76%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cardax stock price history

Cardax stock forecast

Cardax financial statements

Profit Margin

Cardax, Inc. (OTC:CDXI): Profit margin
Dec 2022 0 0
Mar 2023 0 0
Jun 2023 0 0
Sep 2023 0 0
CDXI income statement history

Debt to Assets

Cardax, Inc. (OTC:CDXI): Debt to assets
Mar 2021 1378360 12.73M 923.59%
Mar 2023 0 0
Jun 2023 0 0
Sep 2023 0 0
CDXI balance sheet history

Cash Flow

Cardax, Inc. (OTC:CDXI): Cash Flow
Dec 2022 0 0 0
Mar 2023 0 0 0
Jun 2023 0 0 0
Sep 2023 0 0 0
CDXI cash flow history

Cardax alternative data

Cardax
Employees

Cardax, Inc. (OTC:CDXI): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 10
Dec 2023 10
Jan 2024 10
Feb 2024 10
Mar 2024 10
Apr 2024 10
May 2024 10
Jun 2024 10
Jul 2024 10

Cardax other data

Cardax
Insider Trading

Cardax, Inc. (OTC:CDXI): Insider trades (number of shares)
Period Buy Sel
Feb 2014 500000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
PAULSON CAPITAL (DELAWARE) CORP. 10 percent owner
 Common Stock 500,000 $0.2 $100,000
CDXI insider trading transactions

Cardax
Executives

Insider Compensation
Mr. David G. Watumull (1950) Chairman & Chief Executive Officer
 $214,960
Mr. David M. Watumull (1982) Chief Operating Officer & Chief Financial Officer
 $162,110

Frequently Asked Questions (FAQ)

  • What's the price of Cardax stock today?

    One share of Cardax stock can currently be purchased for approximately $0.

  • When is Cardax's next earnings date?

    Unfortunately, Cardax's (CDXI) next earnings date is currently unknown.

  • Does Cardax pay dividends?

    No, Cardax does not pay dividends.

  • How much money does Cardax make?

    Cardax has a market capitalization of 161.

  • What is Cardax's stock symbol?

    Cardax, Inc. is traded on the OTC under the ticker symbol "CDXI".

  • What is Cardax's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cardax?

    Shares of Cardax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cardax's key executives?

    Cardax's management team includes the following people:

    • Mr. David G. Watumull Chairman & Chief Executive Officer(age: 75, pay: $214,960)
    • Mr. David M. Watumull Chief Operating Officer & Chief Financial Officer(age: 43, pay: $162,110)

  • How many employees does Cardax have?

    As Jul 2024, Cardax employs 10 workers.

  • When Cardax went public?

    Cardax, Inc. is publicly traded company for more then 12 years since IPO on 6 Mar 2013.

  • What is Cardax's official website?

    The official website for Cardax is cardaxpharma.com.

  • Where are Cardax's headquarters?

    Cardax is headquartered at 2800 Woodlawn Drive, Honolulu, HI.

  • How can i contact Cardax?

    Cardax's mailing address is 2800 Woodlawn Drive, Honolulu, HI and company can be reached via phone at +808 4571400.

Cardax company profile:

Cardax, Inc.

cardaxpharma.com
Exchange:

OTC

Full time employees:

10

Industry:

Biotechnology

Sector:

Healthcare

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

+808 4571400
2800 Woodlawn Drive
Honolulu, HI 96822

CIK: 0001544238
ISIN: US14141D2018
CUSIP: 14141D201